For example, we show that GAs in genes such as ARID1A, SMARCA4 and ATR are associated with TMB-high status in a tumour type-specific manner and may thus represent additional biomarkers for immunotherapy in these tumour types. This evidence concerns the gene ARID1A and neoplasm.